WelMed, the Italian digital health startup founded by the two doctors Giulia Franchi and Marco Manzoni, with the support of Alchimia, has concluded a investment round of 5 million euros as part of an operation aimed at carrying out a capital increase of up to 10 million euros by the end of 2021. Alchimia, an investment company headed by Paolo Barletta, contributed as sponsor and coordinator of the fundraising.
«A noteworthy result – declares Marco Manzoni co-founder and CMO WelMed – considering that in Italy overall investments in the world of health-tech startups are still limited. We hope that this operation is an encouragement for the segment ».
WelMed aims to improve medicine thanks to the focus on communication, clinical collaboration and data enhancement through a white label and cloud native digital medicine platform, which is aimed at professionals, healthcare facilities, pharma and insurance companies, who can adopt it in a customized way, to provide digital medicine services to their customers without any need for implementation, installation and maintenance. Today it is used with satisfaction by over 100,000 patients and caregivers.
Giulia Franchi, co-founder and CEO of WelMed, said: «Our mission is to improve people’s quality of life and support stakeholders in the healthcare world to innovate, to provide more accessible, personalized and value-added care. It is a round from Silicon Valley, which testifies how even in Italy the start-ups that do well can do it. The excitement for this new beginning is so much: as a doctor I feel I have the obligation to bring progress to medicine and benefit people, as an entrepreneur I know I have to climb the market in order to have a real impact and, as a woman, I dream of leaving. my little sign in the world. The greatest emotion is being able to do all this together with Marco Manzoni and the new great team of the WelMakers ».
The WelMed solution, which entered the market at the end of 2017, made great strides in 2020 also following the needs that emerged and the regulatory updates on telemedicine that occurred during the Covid-19 pandemic.